This document is scheduled to be published in the Federal Register on 05/02/2019 and available online at https://federalregister.gov/d/2019-08924, and on govinfo.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Development of Medications to Prevent and Treat Opioid Use Disorders

and Overdose (UG3/UH3 (Clinical Trials Optional)

Date: May 22, 2019

Time: 8:00 AM to 5:00 PM

Agenda: To review and evaluate cooperative agreement applications

Place: Hilton Washington/Rockville

1750 Rockville Pike Rockville, MD 20852

1

Contact Person: Ivan K. Navarro, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4242, MSC 9550

Bethesda, MD 20892

301-827-5833

ivan.na varro@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: April 26, 2019

\_\_\_\_\_

Natasha M. Copeland, Program Analyst

Office of Federal Advisory Committee Policy

[FR Doc. 2019-08924 Filed: 5/1/2019 8:45 am; Publication Date: 5/2/2019]